Table 1.
Baseline characteristics.
| Characteristics | Group A: | Group B: |
|---|---|---|
| 3BNC117+RMD | RMD | |
| (n=11) | (n=9) | |
| Age (years) | 40 (33–51) | 51 (38–62) |
| Sex | ||
| Female | 2 (18) | 1 (11) |
| Male | 9 (82) | 8 (89) |
| Ethnicity | ||
| African American | 2 (18) | 3 (33) |
| Caucasian | 8 (73) | 6 (67) |
| Hispanic | 1 (09) | 0 (00) |
| Time since HIV-1 diagnosis (years) | 6 (2–11) | 16 (6–31) |
| Time from HIV-1 diagnosis to ART initiation (years) | 0 (0–10) | 0 (0–2) |
| Time on ART (years) | 5 (2–11) | 10 (6–21) |
| HIV subtype | ||
| A | 1 | 1 |
| B | 9 | 5 |
| Not available | 1 | 3 |
| CD4+ T cell count (cells per mm3)* | 716 (450–1090) | 600 (450–1150) |
| Cell-associated unspliced HIV-1 RNA (copies per million CD4+ T cells)* | 9·2 (0·9–111) | 11·0 (4·9–84·4) |
| Total HIV-1 DNA (copies per million CD4+ T cells)* | 604 (57–3281) | 686 (75–2071) |
| Intact proviral HIV-1 DNA (intact proviruses per million CD4+ T cells)* | 58 (41–162) | 46 (7–124) |
CA usHIV-1 RNA=cell-associated unspliced HIV-1 RNA, IPDA=intact proviral DNA assay, RMD=romidepsin.
Data are n (%) or median (range). ART=antiretroviral therapy, RMD=romidepsin.
*
Analyses performed at first leukaphresis time point (day −14)